SATB2 induction of a neural crest mesenchyme-like program drives melanoma invasion and drug resistance.
Saved in:
| Title: | SATB2 induction of a neural crest mesenchyme-like program drives melanoma invasion and drug resistance. |
|---|---|
| Authors: | Fazio M; Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, United States., van Rooijen E; Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, United States., Dang M; Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, United States., van de Hoek G; Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States., Ablain J; Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, United States., Mito JK; Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Brigham and Women's Hospital, Department of Pathology, Boston, United States., Yang S; Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States., Thomas A; Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States., Michael J; Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States., Fabo T; Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, United States., Modhurima R; Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, United States., Pessina P; Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States., Kaufman CK; Division of Medical Oncology, Department of Medicine, Washington University in Saint Louis, Saint Louis, United States.; Department of Developmental Biology, Washington University in Saint Louis, St. Louis, United States., Zhou Y; Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, United States., White RM; Memorial Sloan Kettering Cancer Center and Weill-Cornell Medical College, New York, United States., Zon LI; Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, United States. |
| Source: | ELife [Elife] 2021 Feb 02; Vol. 10. Date of Electronic Publication: 2021 Feb 02. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: eLife Sciences Publications, Ltd Country of Publication: England NLM ID: 101579614 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-084X (Electronic) Linking ISSN: 2050084X NLM ISO Abbreviation: Elife Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
